Year: 2023

Consolidated gross profit increased 24%;Continued gross margin expansion across all business segments;Increases full year guidance ATCHISON, Kan., Nov. 02, 2023 (GLOBE NEWSWIRE) — MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of distilled spirits, branded spirits, and food ingredient solutions, today reported results for the third quarter ended September 30, 2023. 2023 third quarter consolidated results compared to 2022 third quarter:Sales increased 5% to $211.6 million. Gross profit increased 24% to $73.4 million, representing 34.7% of sales. Operating income decreased 41% to $19.8 million and net income decreased 45% to $13.1 million, primarily due to the impairment of assets and other one-time expenses of $18.3 million related to the planned Atchison distillery closure as well as the increase in fair value of contingent...

Third Quarter Net Revenue $110.4 million, up 20.0% versus Prior Year PeriodRaises 2023 Adjusted EBITDA Forecast AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) — Vital Farms (Nasdaq: VITL), a Certified B Corporation that offers a range of ethically produced foods nationwide, today reported financial results for its third quarter ended September 24, 2023. Financial highlights for the third quarter include:Third Quarter 2023 Net Revenue increase of 20.0% to $110.4 million Third Quarter 2023 Net Income of $4.5 million Third Quarter 2023 Adjusted EBITDA of $9.3 million1“The Vital Farms brand continues to gain new consumers, and our company produced another quarter of strong results, including 20% top-line growth and gross margin above 33%. As a result of our strong year-to-date profitability, we are increasing our full year Adjusted...

Record third quarter revenues of $2.8 billion, up 7.2% compared to third quarter 2022 Net earnings of $148 million or $3.70 diluted earnings per share Third quarter free cash flow1 of $293 million New contract awards of $5.4 billion, resulting in backlog of approximately $49 billion Company reaffirms shipbuilding and Mission Technologies FY23 margin guidance2 Company increases shipbuilding midpoint and Mission Technologies FY23 revenue guidance2 Company increases FY23 free cash flow1 guidance2NEWPORT NEWS, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) — HII (NYSE:HII) reported third quarter 2023 revenues of $2.8 billion, up 7.2% from the third quarter of 2022, driven primarily by growth at its Mission Technologies and Ingalls Shipbuilding segments. Operating income in the third quarter of 2023 was $172 million and operating margin was...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023Updated clinical data at the American Society of Hematology (ASH) meeting in December 2023: Long-term follow-up and sub-group analysis from the FELIX trial of obe-cel and initial data from a study of AUTO8 in multiple myeloma Continued progress with commercial manufacturing facility, The Nucleus, with process performance qualification production phase complete and data package on track to support BLA submission Obe-cel Phase 1 study in refractory systemic lupus erythematosus (SLE) expected to initiate in early 2024 Conference call to be held today at 09:00 am EDT/1:00 pm GMT: Conference...

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) — Peloton Interactive, Inc. (Nasdaq: PTON) has announced its financial results for first quarter fiscal 2024. Please visit the Peloton investor relations website https://investor.onepeloton.com/financial-information/quarterly-results to view the first quarter fiscal 2024 shareholder letter. Today the company will host a conference call and live audio webcast to discuss the results at 8:30 a.m. ET. Additional Call Details: What: Peloton First Quarter Fiscal Year 2024 Earnings Conference Call When: Thursday, November 2, 2023 Time: 8:30 a.m. ET Live Call registration link: https://register.vevent.com/register/BI86001a8ba57e41d2afa35c1ab34a0e75 Live Audio Webcast: https://investor.onepeloton.com/news-and-events/events For those unable to participate in the conference call, a replay will be available...

– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3 ACTIVATE-KidsT Pediatric Study of Mitapivat in PK Deficiency; ACTIVATE-Kids Study Achieves >50% Enrollment – – On Track for Data Readouts in Two Phase 3 Trials of Mitapivat in Thalassemia Next Year and Topline Data for AG-946 in LR-MDS by Year-end 2023 – – U.S. PYRUKYND® (mitapivat) Net Revenue of $7.4 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $872.4 Million as of September 30, 2023 – CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the third quarter ended September 30, 2023. “Agios...